Details
Structure visualisation
Entry information
| Complex | |
| AACDB_ID: | 5824 |
| PDBID: | 8AOK |
| Chains: | B_A |
| Organism: | Homo sapiens, Lama glama |
| Method: | XRD |
| Resolution (Å): | 1.60 |
| Reference: | 10.1016/j.jbc.2022.102769 |
| Antibody | |
| Antibody: | VHH6 VHH |
| Antibody mutation: | No |
| INN (Clinical Trial): | |
| Antigen | |
| Antigen: | Human programmed cell death 1 ligand 1 (PD-L1) D1 |
| Antigen mutation: | No |
| Durg Target: | Q9NZQ7 |
Sequence information
Antibody
Chain: B
Mutation: NULL
| >8AOK_B|Chain B|VHH 6|Lama glama (9844) GEVQLVESGGGLVQAGGSLRLSCAASGRTFSNYHMAWFRQAPGKEREFVAGISWTGRGTYYTDSVKGRFTISRDNAKNTVYLQMNSLKPEDTAVYYCAAEGTLYGSGGRTHQSAYDYWGQGTQVTVSS |
Antigen
Chain: A
Mutation: NULL
| >8AOK_A|Chain A|Programmed cell death 1 ligand 1|Homo sapiens (9606) AFTVTVPKDLYVVEYGSNMTIECKFPVEKELDLAALIVYWEMEDKNIIQFVHGEEDLKVQHSSYRQRARLLKDQLSLGNAALQITDVKLQDAGVYRCMISYGGADYKRITVKVNAPY |
Interaction
1、Solvent accessible surface areas (SASA) were calculated (Naccess V2.1.1) for each residue in antibody and antigen, respectively. The residues with SASA loss in binding of more than 1Å2 were classified as interacting residues.
Interacting residues (ΔSASA based)
| B: ARG27 ASN31 TYR32 HIS33 SER52 TRP53 THR54 ARG56 GLY57 TYR59 GLU99 GLY100 THR101 LEU102 TYR103 GLY104 SER105 ARG108 TYR116 A: ILE54 TYR56 GLU58 GLU60 ASP61 ASN63 GLN66 VAL68 ASP73 VAL76 VAL111 ARG113 MET115 SER117 ALA121 ASP122 TYR123 LYS124 ARG125 |
2、We defined interacting paratope-epitope residues by a distance cutoff of < 5Å . Two amino acids are considered as interacting residues if they have at least one atom within a distance of 5 Å from any atom.
Interacting residues (Atom distance based)
